ENLV

Companies
NASDAQ
Enlivex Therapeutics Ltd.
Health Care
Price Chart
Overview

About ENLV

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Market Cap
$28.0M
Volume
90.5K
Avg. Volume
217.3K
P/E Ratio
-1.5332758
Dividend Yield
0.00%
Employees
56.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.76
Moderate Correlation
Volatility
High (0.84)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for ENLV.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, ENLV shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$28.0M
Volume90.5K
P/E Ratio-1.53
Dividend Yield0.00%
Important Dates
Next Dividend
March 6, 2019
Next Earnings
March 30, 2024
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how ENLV fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025